Lokavant has announced the launch of a study planning solution driven by proprietary historical trial data from more than 2,000 studies involving more than 14,000 investigators, 12,000 healthcare institutions, and real-world data (RWD) sources. The new solution allows clinical trial sponsors and contract research organizations (CROs) to accurately identify the right number, location, and mix of sites for performance and diversity milestones, as well as other feasibility goals for optimum study performance.
In one example, Lokavant used five years of data on chronic obstructive pulmonary disease (COPD) to accurately identify the most efficient and inefficient trial sites for future respiratory trials. Analysis revealed that sponsors and CROs could reduce the number of sites needed for a study by 18% to 36% and still hit patient enrollment targets.
“Bringing greater rigor to the study planning process is critical to successful execution, especially given the high cost and lengthy timelines of trials,” said Milind Kamkolkar, former CDO at Sanofi and co-founder and COO of Paradigm. “This solution is unique as it empowers study teams to predict the odds of completing a study within an allotted time frame and provides visibility into actionable next steps. In this way, Lokavant’s new study planning solution has the potential to dramatically accelerate and optimize trial execution.”
“We are driving an important next step in the evolution of clinical research. Lokavant’s new study planning technology is where clinical trials intersect with predictive analytics,” said Andreas Matern, executive vice president of product development at Lokavant. “With this new solution, our customers gain more precise insights about the potential performance of their clinical trials and sites before it’s too late and too expensive to course correct.”
The new data-powered Study Planning solution will be generally available in Q4 2023 as a standalone product or add-on module to its Clinical Trial Intelligence Platform.
Lokavant Launches New Data-Powered Study Planning Solution to Optimize Clinical Trial Performance. (2023, August 29). Business Wire.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.